Abstract
The effect of the route administration on the distribution of radioiodinated OV-TL 3 F(ab′)2 was studied in Balb/c female mice with intraperitoneal or subcutaneous ovarian carcinoma xenografts. In the intraperitoneal tumour model in which both ascites and solid tumour deposits were present, intraperitoneal administration resulted in a lower estimated radiation dose to blood as compared with intravenous administration. In this model normalization to equal estimated radiation doses to blood for both routes of administration indicated that a twice as high estimated radiation dose can be guided to solid intraperitoneal tumour deposits following intraperitoneal administration. Evacuation of ascitic tumour cells prior to monoclonal antibody injection further increased the estimated radiation dose to solid intraperitoneal tumour deposits following intraperitoneal delivery. Following simultaneous intravenous and intraperitoneal injection of the monoclonal antibody, tissue uptake showed no relevant differences in the subcutaneous tumour model. Overall, the intraperitoneal route of administration was found to be the best choice for therapeutic delivery of iodine-131 labelled monoclonal antibodies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Massuger LFAG, Kenemans P, Claessens RAMJ, Verheijen RHM, Schijf CPT, Strijk SP, Poels LG, van Hoesel RGCM, Corstens FHM. Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab′)2 monoclonal antibody. J Nucl Med 1990; 31: 1802–1810.
Tibben JG, Massuger LFAG, Claessens RAMJ, Schijf CPT, Pak KY, Strijk SP, Kenemans P, Corstens FHM. Tumour detection and localization using 99Tcm-labelled OV-TL 3 Fab'in patients suspected of ovarian cancer. Nucl Med Commun 1992;12:885–893.
DeNardo GL, DeNardo SJ, O'Grady LF, Levy NB, Adams GP, Mills SL. Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. Cancer Res 1990; 50 (Suppl): 1014s-1016s.
Eary JF, Press OW, Badger CC, Durack LD, Richter KY, Addison SJ, Krohn KA, Fisher DR, Porter BA, Williams DL, Martin PJ, Appelbaum FR, Levy R, Brown SL, Miller RA, Nelp WB, Bernstein ID. Imaging and treatment of B-cell lymphoma. J Nucl Med 1990; 31: 1257–1268.
Epenetos AA, Munro AJ, Stewart S, Rampling R, Lambert HE, McKenzie CG, Soutter P, Rahemtulla A, Hooker G, Sivolapenko GB, Snook D, Courtenay-Luck N, Dhokia B, Krausz T, Taylor-Papadimitriou, Durbin H, Bodmer WE. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 1987; 5: 1890–1899.
Finkler NJ, Muto MG, Kassis AI, Weadock K, Tumeh SS, Zurawski VR, Knapp RC. Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer. Gynecol Oncol 1989;34:339–344.
Riva P, Marangolo M, Lazzari S, Agostini M, Sarti G, Moscatelli G, Franceschi G, Spinelli A, Vecchietti G. Locoregional immunotherapy of human ovarian cancer: preliminary results. Nucl Med Biol 1989; 16:659–666.
Massuger LFAG, Boerman OC, Corstens FHM, Verheijen RHM, Claessens RAMJ, Poels LG, van den Broek WJM, Kenemans P. Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and fragments in tumour-bearing athymic mice. Anticancer Res 1991; 11: 2051–2058.
Buchegger F, Chalandon Y, Pèlegrin A, Hardman N, Mach JP. Bone marrow dosimetry in rats using direct tissue counting after injection of radioiodinated intact monoclonal antibodies or F(ab′)2 fragments. JNucl Med 1991; 32: 1414–1421.
Pedley RB, Boden JA, Boden R, Dale R, Begent RHJ. Comparative radioimmunotherapy using intact or F(ab′)2 fragments of 131I anti-CEA antibody in a colonic xenograft model. Br J Cancer 1993; 68: 69–73.
Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, Ozols RF. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intra-abdominal carcinomatosis in mice. Cancer Res 1984;44:5286–5290.
Poels LG, Peters D, van Megen Y, Vooijs GP, Verheijen RHM, Willemen A, van Niekerk CC, Jap PHK, Mungyer G, Kenemans P. Monoclonal antibody against human ovarian tumour-associated antigens. J Natl Cancer Inst 1986; 76: 781–787.
Campbell IA, Freemont PS, Foulkes W, Trowsdale J. An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains. Cancer Res 1992; 52: 5416–5420.
Fraker PJ, Speck JC. Protein and cell membrane iodination with a sparingly soluble chloramide 1,3,4,6-tetrachloro-3,6-diphenylglucoril. Biochem Biophys Res Commun 1978; 80: 849–857.
Lindmo T, Boven E, Cuttila F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72: 77–89.
Badger CC, Krohn KA, Peterson AV, Shulman H,Bernstein ID. Experimental radiotherapy of murine lymphoma with 131I-labeled anti-Thy 1.1 monoclonal antibody. Cancer Res 1985; 45:1536–1544.
Dillman LT. Radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation. MIRD Pamphlet no. 4. The Society of Nuclear Medicine, 1969.
Mosely KR, Battaile A, Knapp RC, Haisma HJ. Localization of radiolabeled F(ab′)2 fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenografts. Int J Cancer 1988; 42: 368–372.
Griffin TW, Collins J, Bokhari F, Stochl M, Brill AB, Ito T, Emond G, Sands H. Intraperitoneal immunoconjugates. Cancer Res 1990; 50 (Suppl): 1031s–1038s.
Rowlinson G, Snook D, Busza A, Epenetos AA. Antibody-guided localization of intraperitoneal tumours following intraperitoneal or intravenous antibody administration. Cancer Res 1987;47:6528–6531.
Boerman OC, Sharkey RM, Aninipot RL, Blumenthal RB, Goldenberg DM. The presence of a concomitant bulky tumor can decrease the uptake and therapeutic efficacy of radiolabeled antibodies in small tumors. Int T Cancer 1992; 51: 470–475.
Ward BG, Wallace K. Localization of the monoclonal antibody HMFG2 after intravenous and intraperitoneal injection into nude mice bearing subcutaneous and intraperitoneal human ovarian cancer xenografts. Cancer Res 1987; 47: 4714–4718.
Barrett JS, Wahl RL, Wagner JG, Brown R, Fisher SJ. Investigations into the route of uptake and pharmacokinetics of intraperitoneally-administered monoclonal antibodies. Transdiaphragmatic blockade of the terminal lymphatics in the rat. Cancer Immunol Immunother 1990; 31: 365–372.
Wahl RL, Barrett J, Geatti O, Liebert M, Wilson BS, Fisher S, Wagner JG. The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage. Cancer Immunol Immunother 1988; 26: 187–201.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tibben, J.G., Massuger, L.F.A.G., Boerman, O.C. et al. Effect of the route of administration on the biodistribution of radioiodinated OV-TL 3 F(ab′)2 in experimental ovarian cancer. Eur J Nucl Med 21, 1183–1190 (1994). https://doi.org/10.1007/BF00182351
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00182351